Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ROCKWELL MEDICAL, INC. amended credit facility of $8.0 million with Innovatus Life Sciences Lending Fund I, LP at the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50% maturing fifth anniversary of the Effective Date.
- Instrument
- credit facility
- Principal
- $8.0 million
- Counterparty
- Innovatus Life Sciences Lending Fund I, LP
- Rate
- the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50%
- Maturity
- fifth anniversary of the Effective Date
- Event
- amendment
Exact text from the filing
for the continuation of term loans initially borrowed on or after the Original Effective Date, in an aggregate outstanding principal amount as of the Effective Date of $8.0 million (the “Term Loans”). The Company will make interest-only payments on the Term Loans for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ROCKWELL MEDICAL, INC. reported three months ended December 31, 2023 results: revenue between $21.3 million and $22.3 million, net income ($2.2) to ($1.2). Guidance reaffirmed.
- Period
- three months ended December 31, 2023
- Revenue
- between $21.3 million and $22.3 million
- Net income
- ($2.2) to ($1.2)
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
8, 2024. 1 Rockwell Medical Preliminary Fourth Quarter and Full-Year 2023 Projected Results Rockwell Medical projects net sales in the fourth quarter of 2023 to be between $21.3 million and $22.3 million, a 10% to 16% increase over net sales of $19.3 million for the same period in 2022; gross profit for the fourth quarter of 2023 to be between $1.6 million and
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ROCKWELL MEDICAL, INC. reported twelve months ended December 31, 2023 results: revenue between $82.8 million and $83.8 million, net income ($9.1) to ($8.1). Guidance reaffirmed.
- Period
- twelve months ended December 31, 2023
- Revenue
- between $82.8 million and $83.8 million
- Net income
- ($9.1) to ($8.1)
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
in the fourth quarter of 2023. Rockwell Medical is narrowing its full-year 2023 guidance and projects net sales for the twelve months ended December 31, 2023 to be between $82.8 million and $83.8 million, a 14% to 15% increase over net sales of $72.8 million in 2022, and gross profit for the full-year 2023 to be between $7.4 million and $8.4 million, an 80% to
View on SEC.gov